Tests acoramidis to prevent heart and nerve disease in people with inherited transthyretin amyloidosis
Tests acoramidis against a placebo in adults carrying a defective TTR gene without symptoms.
Plain-language title generated from the registry record
Registry title: Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Key facts
- Where
- Aarhus N, DenmarkSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who carry a disease-causing TTR gene change but have no symptoms yet. It tests acoramidis against placebo to see if it can prevent or delay transthyretin amyloidosis.
- Age
- 18 to 75 years old.
- Sex
- Men and women can join.
- Disease stage
- No sign of ATTR-CM (heart) or ATTR-PN (nerve) disease. The person's age must be within 10 years younger or older than PADO.
- Earlier treatment
- People cannot join if they had other TTR modifying therapies currently or in the past 1 to 12 months, depending on the drug.
- Biomarker or test result
- A medically-indicated genetic test must show a TTR gene variant known to be pathogenic or likely pathogenic (for example V30M/p.V50M, V122I/p.V142I, T60A/p.T80A).
Main reasons for not taking part
- Signs of ATTR-CM or ATTR-PN
- Other TTR modifying therapies now or recently
- Cannot have cardiac magnetic resonance testing
- Major organ problems such as kidney, liver or heart disease, or neuropathy
- Cancer within 5 years, untreated thyroid disease, type 1 diabetes, active hepatitis B or C, or HIV
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06563895, who can take part
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eidos Therapeutics, a BridgeBio company
- Trial code
- NCT06563895EU 2024-513547-82-00
- Record updated
- 4 August 2026
- Original description
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.Read full original descriptionShow less
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.
Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.
Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.
This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
Inclusion: Male or female ≥ 18 to ≤ 75 years of age inclusive; Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M/p.V50M, V122I/p.V142I, T60A/p.T80A, or all other pathogenic TTR variants); Participant's age is within 10 years younger than or older than PADO.
Exclusion: Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies; Major surgery within the past 3 months or planned during the next 12 months; Contraindication to or inability to undergo cardiac magnetic resonance testing; Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy; Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV; Known hypersensitivity to acoramidis; Evidence of ATTR-CM or ATTR-PN.